You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
AMBIENT LIGHT ACTIVATABLE OPSIN BASED THERAPY FOR AGE-RELATED MACULAR DEGENERATION
SBC: NANOSCOPE TECHNOLOGIES LLC Topic: NEISevere loss of vision occurs due to age-related macular degeneration (AMD) and approximately 15 million people in the US have some form of AMD, which is expected to double by 2050. Most of the current clinical treatments are primarily focused on slowing down the progression of the disease, as there is neither a cure that can stop the degeneration nor a therapy, other than retinal prostheses, that ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing an automated yeast dissection system for aging research
SBC: Innovative BioChips LLC Topic: NIAPROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide
SBC: FirstString Research, Inc Topic: 102PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors
SBC: Onconano Medicine, Inc. Topic: NCIAbstract The goal of this project is to develop IV injectable fluorescent agents for use in intraoperative imaging of peritoneal metastatic tumors. Significance: Peritoneal metastatic cancers have an incidence of 250,000/per year in the US and are primarily treated with surgery. Complete surgical tumor resection is a gold-standard treatment goal that can increase the 5-year patient survival to 50% ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Zinc(II) Sensitive MRI Contrast Agents as Diagnostic Sensors for Tracking Insulin Secretion
SBC: VITALQUAN LIMITED LIABILITY COMPANY Topic: NIDDKABSTRACT SignificanceDiabetes mellitus typeT Dand particularly typeT Dandgtof casesare becoming an increasing burden on socioeconomic resources with vastly increasing patient numbers all over the worldInsulin dependent treatment regimen such as regular insulin injections are well established for both T D and T D but have been associated with a negative impact on the quality of life of patients wit ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Preclinical evaluation of a novel small molecule STAT inhibitor
SBC: FANNIN PARTNERS LLC Topic: NIAIDProject Summary Problem statementAsthma is one of the most common and burdensome of all chronic inflammatory diseasescausing almost lifelong respiratory symptoms to various degrees through a patient s life due to severe airway inflammationairway obstructionand triggered hyper responsivenessAlmostof these individuals experience very severecomplexand heterogeneous disease symptoms that remain intrac ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Additional costs related to formulation, chronic tox and general development of PTI-125
SBC: PAIN THERAPEUTICS, INC. Topic: NIAProject Summary Abstract PTIis a novel small molecule AD therapeutic candidate with a novel target and mechanism of actionPTIbinds and reverses an altered conformation of the scaffolding protein filamin AFLNAto prevent Aandapos s tight binding to and toxic signaling via thenicotinic acetylcholine receptornAChRas well as Aandapos s aberrant activation of toll like receptorTLRHenceby restoring FLNAa ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Administrative Supplement to Promote Diversity in Research and Development Small Businesses
SBC: NEUROENE THERAPEUTICS INC Topic: NINDSAbstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Quantitative Analysis of Single Molecule Microscopy
SBC: Astero Technologies LLC Topic: 400PROJECT SUMMARY ABSTRACTSingle molecule microscopy is a relatively novel technique that allows individual molecules to be imaged using the optical microscopeIt is of major interest to scientists because it enables the observation of cellular processes at the molecular levela task that is not achievable with classical optical imaging approaches due to the cellular processes being obscured by averag ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health